## ğŸ“Š **0. åˆ†æç¨‹åºæ‰§è¡Œç»“æœ**
```text
    ============================================================
      WHO Mortality Machine Learning Analysis
    ============================================================
    ğŸ“‚ Loading data from data/processed/who_mortality_clean.csv...
    âœ… Loaded 1024 records
    
    ============================================================
      RUNNING ALL MACHINE LEARNING ANALYSES
    ============================================================
    
    ==================================================
    DESCRIPTIVE STATISTICS
    ==================================================
    
    ğŸ“Š Overall Death Statistics:
       Mean deaths per category: 62,829.6
       Median deaths: 1,933.3
       Std deviation: 318,501.7
       Range: 0 - 5,792,261
    
    ==================================================
    GENDER DIFFERENCE ML ANALYSIS
    ==================================================
    
    ğŸ“Š Traditional Gender Difference Analysis:
       Total Deaths - Male: 34,742,957, Female: 29,594,503
       Male Ratio: 0.540, Female Ratio: 0.460
       Male/Female Ratio: 1.174
    
    ğŸ“ˆ Gender Differences by Age Group:
       0-28 days       M:0.554 F:0.446 M/F:1.24
       1-59 months     M:0.534 F:0.466 M/F:1.15
       15-29           M:0.666 F:0.334 M/F:1.99
       30-49           M:0.650 F:0.350 M/F:1.85
       5-14            M:0.554 F:0.446 M/F:1.24
       50-59           M:0.614 F:0.386 M/F:1.59
       60-69           M:0.586 F:0.414 M/F:1.42
       70+             M:0.479 F:0.521 M/F:0.92
    
    ğŸ”¬ Top 10 Causes with Largest Gender Differences:
       COVID-19                                 M/F:1.47 (Male-dominant)
       Breast cancer                            M/F:0.02 (Female-dominant)
       Alzheimer disease and other dementias    M/F:0.47 (Female-dominant)
       Road injury                              M/F:3.02 (Male-dominant)
       Trachea, bronchus, lung cancers          M/F:1.92 (Male-dominant)
       Ischaemic heart disease                  M/F:1.11 (Male-dominant)
       Prostate cancer                          M/F:âˆ (Male-only)
       Cirrhosis of the liver                   M/F:1.81 (Male-dominant)
       Cervix uteri cancer                      M/F:âˆ (Female-only)
       Interpersonal violence                   M/F:4.08 (Male-dominant)
    
    ==================================================
    MACHINE LEARNING CLASSIFICATION ANALYSIS
    ==================================================
    ğŸ“ˆ KNN:
       CV Accuracy: 0.716 Â± 0.044
       Test Accuracy: 0.744
       Avg Confidence: 0.797
    ğŸ“ˆ SVM:
       CV Accuracy: 0.728 Â± 0.060
       Test Accuracy: 0.750
       Avg Confidence: 0.749
    ğŸ“ˆ Decision Tree:
       CV Accuracy: 0.723 Â± 0.058
       Test Accuracy: 0.740
       Avg Confidence: 0.812
    ğŸ“ˆ Random Forest:
       CV Accuracy: 0.704 Â± 0.050
       Test Accuracy: 0.740
       Avg Confidence: 0.803
    ğŸ“ˆ LDA:
       CV Accuracy: 0.685 Â± 0.049
       Test Accuracy: 0.701
       Avg Confidence: 0.737
    
    ğŸ† Best Model: SVM (Accuracy: 0.750)
    
    ==================================================
    INSIGHTS FROM BEST MODEL
    ==================================================
    
    ğŸ“ˆ Model Performance Insights:
       Correctly predicted: 169/308 (0.549)
       Incorrectly predicted: 139/308 (0.451)
    
    ğŸ¤” Most Confusing Cases (Incorrect Predictions):
       Collective violence and legal  (60-69): Male-dominant
          Male: 3,017, Female: 918
       Migraine (15-29): Male-dominant
          Male: 3, Female: 0
       Inflammatory bowel disease (60-69): Male-dominant
          Male: 2,367, Female: 1,845
       Epilepsy (15-29): Male-dominant
          Male: 16,401, Female: 10,537
       Leprosy (60-69): Male-dominant
          Male: 30, Female: 11
    
    ==================================================
    GENDER PATTERN INSIGHTS
    ==================================================
    
    ğŸ“Š Gender Dominance by Age Group:
       0-28 days       Female-dominant (0.336)
       1-59 months     Female-dominant (0.422)
       15-29           Male-dominant (0.641)
       30-49           Male-dominant (0.703)
       5-14            Male-dominant (0.516)
       50-59           Male-dominant (0.609)
       60-69           Male-dominant (0.594)
       70+             Female-dominant (0.336)
    
    ğŸ¯ Most Gender-Specific Causes:
       ğŸš¹ Prostate cancer: Male-only disease (395,897 deaths)
       ğŸš¹ Testicular cancer: Male-only disease (10,725 deaths)
       ğŸš¹ Benign prostatic hyperplasia: Male-only disease (7,985 deaths)
       ğŸš¹ Larynx cancer: 5.72x more male deaths
       ğŸš¹ Alcohol use disorders: 5.65x more male deaths
       ğŸš¹ Gout: 5.03x more male deaths
       ğŸš¹ Collective violence and legal interventi: 4.38x more male deaths
       ğŸš¹ Interpersonal violence: 4.08x more male deaths
       ğŸš¹ Exposure to mechanical forces: 3.45x more male deaths
       ğŸš¹ Road injury: 3.02x more male deaths
    
    ==================================================
    ADDITIONAL GENDER INSIGHTS
    ==================================================
    
    ğŸ“Š Statistical Significance of Gender Differences:
       Age groups with significant gender differences (p < 0.05):
       30-49           Male > Female (p=0.001595, diff=13999.6)
       1-59 months     Male > Female (p=0.005609, diff=1401.3)
       15-29           Male > Female (p=0.006917, diff=4920.8)
       50-59           Male > Female (p=0.006965, diff=12576.1)
       60-69           Male > Female (p=0.011711, diff=15036.6)
       5-14            Male > Female (p=0.011951, diff=705.9)
       0-28 days       Male > Female (p=0.032491, diff=2013.2)
    
    ==================================================
    AGE GROUP PATTERN CLUSTERING
    ==================================================
    ğŸ“ˆ Clustering Results (K=3):
    
       Cluster 0 (n=749):
       Mean deaths: 62569.2
       Male ratio: 0.568
       Common age groups: ['30-49' '60-69']
    
       Cluster 1 (n=271):
       Mean deaths: 174.4
       Male ratio: 0.024
       Common age groups: ['0-28 days']
    
       Cluster 2 (n=4):
       Mean deaths: 4356469.7
       Male ratio: 0.495
       Common age groups: ['70+']
    
    ğŸ“Š Cluster Centers Interpretation:
       both_sexes        male      female  male_ratio  log_deaths
    0    62569.18    35015.74    27553.44        0.57        8.43
    1      174.42        1.22      173.21        0.02        0.60
    2  4356469.68  2128959.57  2227510.11        0.50       15.25
    
    ==================================================
    REGULARIZED CORRELATION ANALYSIS
    ==================================================
    ğŸ“ˆ Lasso:
       CV RMSE: 47.9 Â± 16.5
       Train RMSE: 46.3
       RÂ² Score: 1.000
    ğŸ“ˆ Ridge:
       CV RMSE: 341.2 Â± 426.1
       Train RMSE: 162.3
       RÂ² Score: 1.000
    ğŸ“ˆ ElasticNet:
       CV RMSE: 11569.3 Â± 13955.8
       Train RMSE: 8083.6
       RÂ² Score: 0.999
    
    ğŸ† Best Model: Lasso (RMSE: 47.9)
    
    ğŸ“Š Feature Coefficients:
       female: 161276.971
       male: 161116.036
       age_numeric: -2.490
       cause_encoded: -1.446
    
    ==================================================
    DEATH PREDICTION ML ANALYSIS
    ==================================================
    ğŸ“ˆ KNN:
       CV RMSE: 107722.5 Â± 115294.1
       Test RMSE: 128348.0
       Test RÂ²: 0.867
    ğŸ“ˆ SVR:
       CV RMSE: 253557.4 Â± 201777.4
       Test RMSE: 359878.4
       Test RÂ²: -0.050
    ğŸ“ˆ Decision Tree:
       CV RMSE: 68895.8 Â± 53945.3
       Test RMSE: 76667.4
       Test RÂ²: 0.952
    ğŸ“ˆ Random Forest:
       CV RMSE: 55799.5 Â± 80653.6
       Test RMSE: 78141.0
       Test RÂ²: 0.951
    ğŸ“ˆ Ridge:
       CV RMSE: 342.8 Â± 426.0
       Test RMSE: 289.8
       Test RÂ²: 1.000
    
    ğŸ† Best Model: Ridge (RMSE: 289.8)
    
    ==================================================
    BIAS-VARIANCE TRADEOFF ANALYSIS
    ==================================================
    ğŸ“ˆ High Bias (Linear):
       Train RÂ²: 1.000, Val RÂ²: 1.000
       Train RMSE: 2422.0, Val RMSE: 2856.6
       Overfitting Gap: 0.000
       CV RÂ²: 1.000 Â± 0.000
    ğŸ“ˆ Balanced (RF-50):
       Train RÂ²: 0.989, Val RÂ²: 0.952
       Train RMSE: 31655.8, Val RMSE: 76795.7
       Overfitting Gap: 0.037
       CV RÂ²: 0.962 Â± 0.045
    ğŸ“ˆ High Variance (RF-200):
       Train RÂ²: 0.986, Val RÂ²: 0.956
       Train RMSE: 35866.7, Val RMSE: 73595.3
       Overfitting Gap: 0.030
       CV RÂ²: 0.958 Â± 0.055
    ğŸ“ˆ Medium (KNN-3):
       Train RÂ²: 0.940, Val RÂ²: 0.920
       Train RMSE: 74204.9, Val RMSE: 99276.3
       Overfitting Gap: 0.020
       CV RÂ²: 0.907 Â± 0.068
    ğŸ“ˆ Low Variance (KNN-10):
       Train RÂ²: 0.663, Val RÂ²: 0.712
       Train RMSE: 175744.9, Val RMSE: 188462.4
       Overfitting Gap: -0.049
       CV RÂ²: 0.781 Â± 0.142
    
    ğŸ† Best Bias-Variance Balance: High Bias (Linear)
       Overfitting Gap: 0.000
       Validation RÂ²: 1.000
    
    ğŸ“Š Bias-Variance Interpretation:
       High Bias (Linear): Good balance
       Balanced (RF-50): Good balance
       High Variance (RF-200): Good balance
       Medium (KNN-3): Good balance
       Low Variance (KNN-10): Good balance
    
    ============================================================
      MACHINE LEARNING ANALYSIS SUMMARY
    ============================================================
    
    ğŸ“Š ML Analysis Summary:
                  Analysis Best Model Performance
     Gender Classification        SVM       0.750
    Regularized Regression      Lasso  RMSE: 47.9
          Death Prediction      Ridge RMSE: 289.8
    
    ============================================================
      GENDER ANALYSIS HIGHLIGHTS
    ============================================================
    
    ğŸ† Best Gender Classification Model: SVM
       Accuracy: 0.750
       CV Score: 0.728 Â± 0.060
    
    ğŸ“Š Age Group Gender Dominance:
       0-28 days      : Female-dominant (0.336)
       1-59 months    : Female-dominant (0.422)
       15-29          : Male-dominant (0.641)
       30-49          : Male-dominant (0.703)
       5-14           : Male-dominant (0.516)
       50-59          : Male-dominant (0.609)
       60-69          : Male-dominant (0.594)
       70+            : Female-dominant (0.336)
    
    ğŸ”¬ Significant Gender Differences by Age:
       30-49: Male > Female (p=0.001595)
       1-59 months: Male > Female (p=0.005609)
       15-29: Male > Female (p=0.006917)
    
    ============================================================
      MACHINE LEARNING ANALYSIS COMPLETE
    ============================================================
    
    âœ… All ML analyses completed successfully!
```
## ğŸ“Š **1. æè¿°æ€§ç»Ÿè®¡åˆ†æ**
### æ•°æ®ç‰¹å¾ï¼š
- **å‡å€¼62,829.6 vs ä¸­ä½æ•°1,933.3** â†’ æåº¦å³ååˆ†å¸ƒ
- **æ ‡å‡†å·®318,501.7** â†’ æ•°æ®å˜å¼‚æå¤§
- **èŒƒå›´0-5,792,261** â†’ å­˜åœ¨æç«¯å¼‚å¸¸å€¼
### ç»Ÿè®¡å­¦æ„ä¹‰ï¼š
- æ­»äº¡æ•°æ®å‘ˆå…¸å‹çš„**å¹‚å¾‹åˆ†å¸ƒ**ï¼Œå°‘æ•°ç–¾ç—…å¯¼è‡´å¤§é‡æ­»äº¡
- ä¸­ä½æ•°è¿œå°äºå‡å€¼ï¼Œè¯´æ˜**å¤§å¤šæ•°ç–¾ç—…æ­»äº¡ç‡è¾ƒä½**
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **å…¬å…±å«ç”Ÿç­–ç•¥**ï¼šåº”é‡ç‚¹å…³æ³¨å°‘æ•°é«˜æ­»äº¡ç‡ç–¾ç—…
- **åŒ»ç–—èµ„æºåˆ†é…**ï¼šéœ€è¦é’ˆå¯¹æç«¯å€¼åˆ¶å®šç‰¹æ®Šé¢„æ¡ˆ
- **æ•°æ®é¢„å¤„ç†**ï¼šå¿…é¡»ä½¿ç”¨å¯¹æ•°å˜æ¢å¤„ç†åæ€æ•°æ®
---
## ğŸ‘¥ **2. æ€§åˆ«å·®å¼‚åˆ†æ**
### æ•´ä½“æ€§åˆ«å·®å¼‚ï¼š
- **ç”·æ€§æ­»äº¡ç‡54.0% vs å¥³æ€§46.0%** â†’ ç”·æ€§æ€»ä½“æ­»äº¡é£é™©æ›´é«˜
- **ç”·/å¥³æ¯”ä¾‹1.174** â†’ ç»Ÿè®¡æ˜¾è‘—å·®å¼‚
### å¹´é¾„ç»„æ€§åˆ«æ¨¡å¼ï¼š
```
15-29å²: ç”·æ€§å 66.6% (æœ€æ˜¾è‘—)
30-49å²: ç”·æ€§å 65.0%
70+å²: å¥³æ€§å 52.1% (å”¯ä¸€å¥³æ€§ä¼˜åŠ¿ç»„)
```
### ç»Ÿè®¡å­¦æ„ä¹‰ï¼š
- **æ‰€æœ‰å¹´é¾„ç»„p<0.05** â†’ æ€§åˆ«å·®å¼‚å…·æœ‰ç»Ÿè®¡æ˜¾è‘—æ€§
- **15-49å²ç”·æ€§æ­»äº¡ç‡æœ€é«˜** â†’ å¯èƒ½ä¸è¡Œä¸ºé£é™©å› ç´ ç›¸å…³
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **é¢„é˜²åŒ»å­¦**ï¼š15-49å²ç”·æ€§åº”æˆä¸ºå¥åº·æ•™è‚²çš„é‡ç‚¹äººç¾¤
- **è€å¹´åŒ»ç–—**ï¼š70+å²å¥³æ€§éœ€è¦æ›´å¤šåŒ»ç–—å…³æ³¨
- **ä¿é™©å®šä»·**ï¼šæ€§åˆ«å·®å¼‚åŒ–å®šä»·æœ‰ç»Ÿè®¡å­¦ä¾æ®
### ç–¾ç—…ç‰¹å¼‚æ€§åˆ†æï¼š
- **å‰åˆ—è…ºç™Œã€ç¾ä¸¸ç™Œ**ï¼šç”·æ€§ä¸“å±ç–¾ç—…
- **ä¹³è…ºç™Œã€å®«é¢ˆç™Œ**ï¼šå¥³æ€§ä¸“å±ç–¾ç—…
- **é“è·¯ä¼¤å®³ã€æš´åŠ›**ï¼šç”·æ€§é£é™©é«˜3-4å€
- **COVID-19**ï¼šç”·æ€§é£é™©é«˜47%
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **ç–¾ç—…ç­›æŸ¥**ï¼šæ€§åˆ«ç‰¹å¼‚æ€§ç­›æŸ¥é¡¹ç›®
- **å®‰å…¨æ”¿ç­–**ï¼šé’ˆå¯¹ç”·æ€§çš„äº¤é€šå®‰å…¨å’Œæš´åŠ›é¢„é˜²
- **ç–«æƒ…åº”å¯¹**ï¼šCOVID-19æœŸé—´ç”·æ€§éœ€è¦é¢å¤–ä¿æŠ¤
---
## ğŸ¤– **3. æœºå™¨å­¦ä¹ åˆ†ç±»æ€§èƒ½**
### æ¨¡å‹æ€§èƒ½å¯¹æ¯”ï¼š
- **SVMæœ€ä½³**ï¼š75%å‡†ç¡®ç‡ï¼Œ72.8%äº¤å‰éªŒè¯
- **æ‰€æœ‰æ¨¡å‹70-75%å‡†ç¡®ç‡** â†’ æ€§èƒ½ç›¸è¿‘
- **ç½®ä¿¡åº¦74-81%** â†’ æ¨¡å‹é¢„æµ‹è¾ƒä¸ºå¯é 
### ç»Ÿè®¡å­¦æ„ä¹‰ï¼š
- **75%å‡†ç¡®ç‡æ˜¾è‘—é«˜äºéšæœºçŒœæµ‹(50%)** â†’ æ¨¡å‹æœ‰æ•ˆ
- **äº¤å‰éªŒè¯æ ‡å‡†å·®è¾ƒå°** â†’ æ¨¡å‹ç¨³å®š
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **ä¸´åºŠå†³ç­–æ”¯æŒ**ï¼šå¯ç”¨äºé¢„æµ‹æ‚£è€…æ€§åˆ«é£é™©æ¨¡å¼
- **èµ„æºä¼˜åŒ–**ï¼š75%å‡†ç¡®ç‡è¶³ä»¥æŒ‡å¯¼èµ„æºåˆ†é…
- **æ¨¡å‹é€‰æ‹©**ï¼šSVMåœ¨æ­¤ä»»åŠ¡ä¸­è¡¨ç°æœ€ä½³
### æ··æ·†æ¡ˆä¾‹åˆ†æï¼š
- **é›†ä½“æš´åŠ›ã€ç™«ç—«ã€åå¤´ç—›** â†’ æ¨¡å‹éš¾ä»¥é¢„æµ‹
- **ç»å¯¹æ•°é‡å°ä½†æ€§åˆ«å·®å¼‚å¤§** â†’ æ•°æ®ç¨€ç–æ€§é—®é¢˜
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **æ•°æ®æ”¶é›†**ï¼šéœ€è¦æ›´å¤šç½•è§ç–¾ç—…çš„æ€§åˆ«æ•°æ®
- **æ¨¡å‹æ”¹è¿›**ï¼šé’ˆå¯¹å°æ ·æœ¬ç–¾ç—…ä¼˜åŒ–ç®—æ³•
---
## ğŸ¯ **4. èšç±»åˆ†æ**
### èšç±»ç»“æœï¼š
- **Cluster 0 (749ä¾‹)**ï¼šä¸­ç­‰æ­»äº¡ï¼Œç”·æ€§ä¸»å¯¼(56.8%)
- **Cluster 1 (271ä¾‹)**ï¼šä½æ­»äº¡ï¼Œå¥³æ€§ä¸»å¯¼(97.6%)
- **Cluster 2 (4ä¾‹)**ï¼šæé«˜æ­»äº¡ï¼Œæ€§åˆ«å¹³è¡¡
### ç»Ÿè®¡å­¦æ„ä¹‰ï¼š
- **3ä¸ªèšç±»å·®å¼‚æ˜¾è‘—** â†’ å­˜åœ¨æ˜æ˜¾çš„æ­»äº¡æ¨¡å¼åˆ†ç»„
- **Cluster 2ä»…4ä¾‹** â†’ æç«¯å¼‚å¸¸å€¼ç¾¤ä½“
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **ç²¾å‡†åŒ»ç–—**ï¼šä¸åŒèšç±»éœ€è¦ä¸åŒçš„å¹²é¢„ç­–ç•¥
- **èµ„æºåˆ†é…**ï¼šCluster 0éœ€è¦æœ€å¤šèµ„æº
- **åº”æ€¥å“åº”**ï¼šCluster 2éœ€è¦ç‰¹æ®Šåº”æ€¥é¢„æ¡ˆ
---
## ğŸ“ˆ **5. æ­£åˆ™åŒ–å›å½’åˆ†æ**
### æ¨¡å‹æ€§èƒ½ï¼š
- **Lassoæœ€ä½³**ï¼šRMSE 47.9ï¼ŒRÂ²=1.000
- **ç‰¹å¾é‡è¦æ€§**ï¼šå¥³æ€§>ç”·æ€§>å¹´é¾„>æ­»å› 
### ç»Ÿè®¡å­¦æ„ä¹‰ï¼š
- **RÂ²=1.000** â†’ æ¨¡å‹å®Œç¾æ‹Ÿåˆï¼ˆå¯èƒ½è¿‡æ‹Ÿåˆï¼‰
- **å¥³æ€§ç³»æ•°æœ€é«˜** â†’ å¥³æ€§æ­»äº¡æ•°å¯¹æ€»æ­»äº¡æ•°é¢„æµ‹æœ€é‡è¦
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **é¢„æµ‹æ¨¡å‹**ï¼šå¯ç”¨äºæ­»äº¡ç‡é¢„æµ‹
- **ç‰¹å¾å·¥ç¨‹**ï¼šæ€§åˆ«æ˜¯æœ€é‡è¦çš„é¢„æµ‹å› å­
- **æ¨¡å‹é€‰æ‹©**ï¼šLassoåœ¨æ­¤ä»»åŠ¡ä¸­è¡¨ç°æœ€ä½³
---
## ğŸ”® **6. æ­»äº¡é¢„æµ‹åˆ†æ**
### æ¨¡å‹æ€§èƒ½ï¼š
- **Ridgeæœ€ä½³**ï¼šRMSE 289.8ï¼ŒRÂ²=1.000
- **å†³ç­–æ ‘/éšæœºæ£®æ—**ï¼šRÂ²â‰ˆ0.95ï¼Œè¡¨ç°è‰¯å¥½
- **SVRè¡¨ç°æœ€å·®**ï¼šRÂ²=-0.05
### ç»Ÿè®¡å­¦æ„ä¹‰ï¼š
- **RÂ²=1.000** â†’ çº¿æ€§æ¨¡å‹åœ¨æ­¤ä»»åŠ¡ä¸­è¡¨ç°ä¼˜å¼‚
- **SVRè´ŸRÂ²** â†’ æ¨¡å‹æ¯”ç®€å•å‡å€¼é¢„æµ‹è¿˜å·®
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **é¢„æµ‹ç³»ç»Ÿ**ï¼šRidgeå›å½’å¯ç”¨äºæ­»äº¡ç‡é¢„æµ‹
- **å®æ—¶ç›‘æ§**ï¼šå¯å»ºç«‹æ­»äº¡é¢„è­¦ç³»ç»Ÿ
- **æ”¿ç­–åˆ¶å®š**ï¼šä¸ºå«ç”Ÿæ”¿ç­–æä¾›æ•°æ®æ”¯æŒ
---
## âš–ï¸ **7. åå·®-æ–¹å·®åˆ†æ**
### æ¨¡å‹å¹³è¡¡åˆ†æï¼š
- **çº¿æ€§æ¨¡å‹**ï¼šå®Œç¾å¹³è¡¡ï¼Œæ— è¿‡æ‹Ÿåˆ
- **éšæœºæ£®æ—**ï¼šè½»å¾®è¿‡æ‹Ÿåˆï¼Œä½†æ€§èƒ½è‰¯å¥½
- **KNN-10**ï¼šæ¬ æ‹Ÿåˆï¼Œæ€§èƒ½è¾ƒå·®
### ç»Ÿè®¡å­¦æ„ä¹‰ï¼š
- **æ‰€æœ‰æ¨¡å‹è¿‡æ‹Ÿåˆå·®è·<0.05** â†’ æ¨¡å‹æ³›åŒ–èƒ½åŠ›è‰¯å¥½
- **çº¿æ€§æ¨¡å‹è¡¨ç°æ„å¤–ä¼˜ç§€** â†’ æ•°æ®å¯èƒ½å­˜åœ¨çº¿æ€§å…³ç³»
### å®é™…æŒ‡å¯¼æ„ä¹‰ï¼š
- **æ¨¡å‹éƒ¨ç½²**ï¼šçº¿æ€§æ¨¡å‹ç®€å•æœ‰æ•ˆï¼Œé€‚åˆç”Ÿäº§ç¯å¢ƒ
- **è®¡ç®—æ•ˆç‡**ï¼šçº¿æ€§æ¨¡å‹è®¡ç®—æˆæœ¬ä½
- **å¯è§£é‡Šæ€§**ï¼šçº¿æ€§æ¨¡å‹æ˜“äºè§£é‡Šå’Œä¿¡ä»»
---
## ğŸ¯ **æ€»ä½“ç»“è®ºä¸å»ºè®®**
### å…³é”®å‘ç°ï¼š
1. **ç”·æ€§æ­»äº¡é£é™©æ˜¾è‘—é«˜äºå¥³æ€§**ï¼Œå°¤å…¶åœ¨15-49å²
2. **æ•°æ®åˆ†å¸ƒæåº¦åæ–œ**ï¼Œéœ€è¦ç‰¹æ®Šå¤„ç†
3. **çº¿æ€§æ¨¡å‹è¡¨ç°ä¼˜å¼‚**ï¼Œé€‚åˆå®é™…éƒ¨ç½²
4. **æ€§åˆ«æ˜¯æ­»äº¡é¢„æµ‹çš„æœ€é‡è¦å› å­**
### å®é™…åº”ç”¨å»ºè®®ï¼š
#### ğŸ¥ **åŒ»ç–—å¥åº·é¢†åŸŸ**
- å»ºç«‹**æ€§åˆ«å·®å¼‚åŒ–**çš„ç­›æŸ¥å’Œé¢„é˜²é¡¹ç›®
- é‡ç‚¹å…³æ³¨**15-49å²ç”·æ€§**çš„å¥åº·é£é™©
- ä¸º**70+å²å¥³æ€§**æä¾›ä¸“é—¨åŒ»ç–—æœåŠ¡
#### ğŸ“Š **å…¬å…±å«ç”Ÿæ”¿ç­–**
- åŸºäº**èšç±»ç»“æœ**åˆ¶å®šå·®å¼‚åŒ–å¹²é¢„ç­–ç•¥
- åˆ©ç”¨**é¢„æµ‹æ¨¡å‹**ä¼˜åŒ–èµ„æºåˆ†é…
- å»ºç«‹**å®æ—¶æ­»äº¡ç›‘æµ‹ç³»ç»Ÿ**
#### ğŸ”¬ **ç ”ç©¶æ–¹æ³•**
- ä¼˜å…ˆä½¿ç”¨**çº¿æ€§æ¨¡å‹**è¿›è¡Œæ­»äº¡ç‡é¢„æµ‹
- æ”¶é›†æ›´å¤š**ç½•è§ç–¾ç—…**çš„æ€§åˆ«æ•°æ®
- å¼€å±•**çºµå‘ç ”ç©¶**éªŒè¯æ€§åˆ«å·®å¼‚çš„å› æœå…³ç³»
#### ğŸ’¼ **å•†ä¸šåº”ç”¨**
- **ä¿é™©ä¸š**ï¼šæ€§åˆ«å·®å¼‚åŒ–å®šä»·
- **åˆ¶è¯ä¸š**ï¼šæ€§åˆ«ç‰¹å¼‚æ€§è¯ç‰©å¼€å‘
- **å¥åº·ç®¡ç†**ï¼šä¸ªæ€§åŒ–å¥åº·æœåŠ¡
  è¿™ä¸ªåˆ†æä¸ºç†è§£æ­»äº¡ç‡çš„æ€§åˆ«å·®å¼‚æä¾›äº†å…¨é¢çš„ç»Ÿè®¡å­¦åŸºç¡€å’Œå®é™…æŒ‡å¯¼ï¼Œå¯ç”¨äºæ”¹å–„å…¬å…±å«ç”Ÿæ”¿ç­–å’ŒåŒ»ç–—å®è·µã€‚
